TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24918629
Drug: Conventional ventilation
Normalized name: VENTILATOR FILTER,THERMOFLO #6000S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional ventilation (10 mL/kg tidal volume, 0 cm H2O PEEP)
Study: 22569835
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg/day added to interferon beta‐1b
Study: 22569835
Drug: Interferon beta‐1b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon beta‐1b monotherapy
Study: 11192305
Drug: Heparin pretreatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin pretreatment (HP)
Study: 11192305
Drug: Non-heparin pretreatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-heparin pretreatment (NHP)
Study: 25611962
Drug: Tadalafil (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil (1 mg/kg daily)
Study: 25611962
Drug: Tadalafil administration
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tadalafil administration
Study: 25649903
Drug: Laparoscopy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopy with fast-track treatment (LAFT)
Study: 25649903
Drug: Open surgery
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open surgery with fast-track treatment (OSFT)
Study: 25649903
Drug: Laparoscopy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopy with conventional treatment (LAC)
Study: 25649903
Drug: Open surgery
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open surgery with conventional treatment (OSC)
Study: 12880608
Drug: Nutritional supplementation
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplementation (400 ml daily of a supplement enriched with protein, arginine, zinc and antioxidants)
Study: 12880608
Drug: Placebo (non-caloric,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (non-caloric, water-based supplement)
Study: 11082935
Drug: Anthocyanins administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthocyanins administered to 50 women
Study: 11082935
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered to 55 women
Study: 9361661
Drug: Telephone Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone Cognitive Assessment Battery (TCAB) administered before in-person assessment
Study: 1489122
Drug: Atropine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (0.5 mg intranasally)
Study: 20354453
Drug: Gemcitabine 1000
Normalized name: gemcitabine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1000 mg/m on days 1 and 8 (G)
Study: 20354453
Drug: Gemcitabine 1000
Normalized name: gemcitabine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1000 mg/m on days 1 and 8 plus docetaxel 75 mg/m on day 1 (GD)
Study: 12633794
Drug: PMLR with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PMLR with optimal medical therapy (n = 36)
Study: 12633794
Drug: Optimal medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical therapy alone (n = 37)
Study: 10852758
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (IB) plus albuterol
Study: 10852758
Drug: Albuterol plus
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol plus placebo (control)
Study: 8261405
Drug: Oral VP16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral VP16 daily for up to 21 days (Arm A)
Study: 8261405
Drug: Oral VP16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral VP16 daily for up to 21 days plus concomitant GM-CSF at 5 micrograms/kg/day (Arm B)
Study: 8261405
Drug: Oral VP16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral VP16 daily for up to 21 days plus pretreatment with GM-CSF (Arm C)
Study: 3913184
Drug: Adequate medical
Normalized name: Adequan
DrugBank: Polysulfated glycosaminoglycan (DB11538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adequate medical treatment
Study: 30635781
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy regimen comprising mainly of anthracyclines and cytarabine (arm A)
Study: 21329971
Drug: Vero-cell-culture-derived influenza
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vero-cell-culture-derived influenza vaccine
Study: 17192500
Drug: 15-mg pioglitazone/500-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-mg pioglitazone/500-mg metformin fixed-dose combination tablets
Study: 17192500
Drug: 15-mg pioglitazone/500-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-mg pioglitazone/500-mg metformin coadministration of commercial tablets
Study: 17192500
Drug: 15-mg pioglitazone/850-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-mg pioglitazone/850-mg metformin fixed-dose combination tablets
Study: 17192500
Drug: 15-mg pioglitazone/850-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-mg pioglitazone/850-mg metformin coadministration of commercial tablets
Study: 15358467
Drug: Mifepristone 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 75 mg in capsule form followed by misoprostol 600 microg
Study: 15358467
Drug: Mifepristone 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 150 mg in tablet form followed by misoprostol 600 microg
Study: 1417013
Drug: Ondansetron (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (4 mg intravenous injection)
Study: 1417013
Drug: Rescue medication
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue medication (4 mg intravenous dose of ondansetron)
Study: 26159792
Drug: Uric Acid
Normalized name: Uric acid
DrugBank: Uric acid (DB08844)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uric Acid (UA) 1000 mg
Study: 18188581
Drug: Creatine (CR)
DrugBank: Creatine (DB00148)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Creatine (CR) supplementation (approximately 10 g day(-1) over 3 months)
Study: 12719441
Drug: Perindopril (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (2 to 4 mg, n=28)
Study: 12719441
Drug: Telmisartan (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (80 to 160 mg, n=29)
Study: 12719441
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS (30 to 60 mg, n=28)
Study: 12719441
Drug: Amlodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5 to 10 mg, n=28)
Study: 12719441
Drug: Atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50 to 100 mg, n=29)
Study: 12719441
Drug: Nebivolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol (5 to 10 mg, n=28)
Study: 10818412
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate (CA) COC (2 mg CA + 0.035 mg ethinylestradiol)
Study: 10818412
Drug: Desogestrel (D)
Normalized name: Desogestrel
DrugBank: Desogestrel (DB00304)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desogestrel (D) COC (0.150 mg D + 0.030 mg ethinylestradiol)
Study: 8804868
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg each morning and clarithromycin 500 mg three times daily for 2 weeks
Study: 8804868
Drug: Famotidine 40
Normalized name: famotidine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 40 mg twice daily and clarithromycin 500 mg three times daily for 2 weeks
Study: 1611221
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation of 800 mg daily (as calcium lactate gluconate)
Study: 1611221
Drug: Load-bearing exercise
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Load-bearing exercise four times a week plus a daily placebo tablet
Study: 1611221
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation daily and load-bearing exercise four times a week
Study: 1611221
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet daily
Study: 27555316
Drug: Aspirin for
Normalized name: Aspirin 81 MG Oral Tablet, Chewable [ASPIRIN FOR CHILDREN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin for 5 days
Study: 26069138
Drug: Right lateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Right lateral position (group L)
Study: 17486348
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose steroid treatment for optic nerve neuritis
Study: 17486348
Drug: Steroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid treatment for traumatic optic neuropathy
Study: 16294137
Drug: Daily alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily alendronate therapy
Study: 31318038
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine at a dose of 2 mcg/kg (max 100 mcg)
Study: 31318038
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam at a dose of 0.5 mg/kg (max 15 mg)
Study: 21920001
Drug: Ramosetron 5μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramosetron 5μg once daily
Study: 19369404
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) - target dosage 3 g/d
Study: 19369404
Drug: Intravenous cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cyclophosphamide (IVC) - 0.5 to 1.0 g/m(2) in monthly pulses
Study: 19369404
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received prednisone, tapered from a maximum starting dosage of 60 mg/d
Study: 15522039
Drug: Iontophoretic administration
Normalized name: Sumatriptan Iontophoretic Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iontophoretic administration of acetylcholine (ACh)
Study: 8324641
Drug: Primary chemotherapy
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary chemotherapy (cyclophosphamide, methotrexate, and 5-fluorouracil)
Study: 3526151
Drug: Diltiazem (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (90 mg every six hours)
Study: 29185022
Drug: Quetiapine ER
Normalized name: quetiapine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine ER (daily dose range 50 to 800 mg)
Study: 29185022
Drug: Aripiprazole (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (daily dose range 2.5 to 30 mg)
Study: 20829157
Drug: Cold lateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold lateral compaction with 0.02 taper gutta‐percha cones and AH 26 sealer cement
Study: 20829157
Drug: Cold lateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold lateral compaction with 0.02 taper Resilon cones and Epiphany sealer
Study: 20829157
Drug: Single cone
Normalized name: Pinus strobus cone extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single cone technique with 0.04 taper Resilon cones and Epiphany sealer
Study: 19055278
Drug: Acupuncture-medicine group
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture-medicine group (scalp electroacupuncture + Nimodipine)
Study: 19055278
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (Nimodipine only)
Study: 19055278
Drug: Acupuncture-medicine group
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture-medicine group and Electroacupuncture group
Study: 7583550
Drug: Major locus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Major locus with a codominant mixture model including sex, age, plasma concentrations of apoAI and triglycerides, exogenous sex hormone use, and menopausal status.
Study: 2285001
Drug: Naftidrofuryl (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naftidrofuryl (oral formulation)
Study: 29955161
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (48IU/day, n=53)
Study: 10572081
Drug: PEG‐rHuMGDF (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐rHuMGDF (2.5 microg/kg/d or 5 microg/kg/d for up to 21 doses)
Study: 10572081
Drug: PEG‐rHuMGDF (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐rHuMGDF (2.5 microg/kg, single dose) and 7 daily doses of 2.5 microg/kg
Study: 26959810
Drug: Atorvastatin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin treatment group
Study: 26959810
Drug: Non-treatment mTBI
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-treatment mTBI group
Study: 18560642
Drug: Amalgam plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amalgam plus dentin adhesive plus composite resin with modified preparation design (ADACM)
Study: 20031608
Drug: Verapamil SR
Normalized name: Dom-Verapamil SR
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Verapamil SR treatment
Study: 17257175
Drug: dexamethasone 4
Normalized name: dexamethasone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: dexamethasone 4 mg i.v.
Study: 17257175
Drug: betamethasone 12
Normalized name: Betamethasone 120 microgram/mL oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: betamethasone 12 mg i.m.
Study: 18080351
Drug: 0.5% PRO
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% PRO 2000 or matched placebo gel
Study: 9382514
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of 5-FU, epirubicin and MMC (FEM group: n=7)
Study: 9382514
Drug: Other antineoplastic
Normalized name: OTHER ANTINEOPLASTIC AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antineoplastic agents (non-FEM group: n=10)
Study: 2875907
Drug: Temelastine 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temelastine 50 mg
Study: 2875907
Drug: Temelastine 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temelastine 100 mg
Study: 2875907
Drug: Temelastine 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temelastine 200 mg
Study: 2875907
Drug: Chlorpheniramine 4
Normalized name: chlorpheniramine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine 4 mg (Control)
Study: 24072969
Drug: Self-administered training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered training
Study: 19263014
Drug: OMM: omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMM: omeprazole 20 mg twice a day, moxifloxacin 400 mg/day, metronidazole 500 mg three times a day
Study: 19263014
Drug: OBMT: omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: OBMT: omeprazole 20 mg twice a day, colloidal bismuth subcitrate 120 mg four times a day, metronidazole 500 mg three times a day, tetracycline 500 mg four times a day
Study: 8304833
Drug: rPDGF‐BB 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: rPDGF‐BB 100 micrograms/mL
Study: 8304833
Drug: rPDGF‐BB 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: rPDGF‐BB 300 micrograms/mL
Study: 16991062
Drug: Bilateral sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral sequential total knee arthroplasty under one anaesthesia session
Study: 15152279
Drug: Octreotide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (100 microg three times daily subcutaneously)
Study: 9274455
Drug: i.v. 5-dFUR
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. 5-dFUR 3000 mg/m2 with L-leucovorin 25 mg/dose on days 1-5, every 3 weeks
Study: 9274455
Drug: oral 5-dFUR
Normalized name: 5'-DFUR
DrugBank: Doxifluridine (DB12947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral 5-dFUR 1200 mg/m2 for 5 days followed by 5 days off with oral L-leucovorin 25 mg/dose 2 h before 5-dFUR
Study: 9274455
Drug: oral 5-dFUR
Normalized name: 5'-DFUR
DrugBank: Doxifluridine (DB12947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral 5-dFUR
Study: 3729450
Drug: Estradiol administration
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol administration every 7 days
Study: 3729450
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of OK-432 or LENTINAN
Study: 24278177
Drug: Formalin-inactivated EV71
Normalized name: formalin
DrugBank: Formaldehyde (DB03843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Formalin-inactivated EV71 vaccine candidate (EV71vac) at 5- and 10-µg doses
Study: 21068104
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of the last disease-modifying antirheumatic drug (DMARD) after achieving DAS < 1.6 for ≥ 6 months.
Study: 21068104
Drug: Restarting treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restarting treatment with DMARD after DAS increased to ≥ 1.6.
Study: 21068104
Drug: Patients who
Normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who restarted treatment during the year of DAS increase.
Study: 8428895
Drug: quazepam 15
Normalized name: quazepam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: quazepam 15 mg
Study: 23991629
Drug: CSII with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSII with metformin
Study: 16511428
Drug: DNA prime,
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNA prime, recombinant fowlpox virus boost vaccine (1 mg pHIS-HIV-B at weeks 0 and 4, 5 x 10^7 pfu rFPV-HIV-B at week 8)
Study: 8768868
Drug: CPA‐100 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPA‐100 (100 mg/day) + TE (100 mg/week)
Study: 8768868
Drug: CPA‐50 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPA‐50 (50 mg/day) + TE (100 mg/week)
Study: 8768868
Drug: TE (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: TE (100 mg/week) alone
Study: 1881954
Drug: Pulsed electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pulsed electrical stimulation (30 minutes, twice daily, pulse frequency of 128 pps, peak amplitude of 29.2 mA) for chronic dermal ulcers.
Study: 1881954
Drug: Sham electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sham electrical stimulation (same protocol as treatment group).
Study: 3106459
Drug: GHRH 1‐40
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH 1‐40 (1 microgram/Kg bw) iv at time 0 plus TRH (6 micrograms/min) infusion between ‐30 and +120 min
Study: 3106459
Drug: TRH (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRH (6 micrograms/min) infusion between ‐30 and +120 min
Study: 30279333
Drug: Whole milk
Normalized name: Calcium fortified whole milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole milk supplementation (250 mL/day for four weeks)
Study: 26689520
Drug: Peritubal analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peritubal analgesic infiltration with 10mL of bupivacaine
Study: 18471347
Drug: Vildagliptin/metformin (50/1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin/metformin (50/1000 mg) fixed-dose combination tablet after a high-fat meal
Study: 10686266
Drug: Repetitive transcranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repetitive transcranial magnetic stimulation (rTMS) at 90% power of the motor threshold, stimulation frequency of 10 Hz for either 2 sec or 6 sec for 20 trains, treated for up to 20 treatment days.
Study: 10686266
Drug: Electroconvulsive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroconvulsive therapy (ECT) performed according to standard protocols.
Study: 8336746
Drug: Combined out‐patient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined out‐patient therapy program (physical exercise, dietary counseling, psychological support)
Study: 3511478
Drug: True ultrasound
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: True ultrasound (US) therapy
Study: 3511478
Drug: Sham ultrasound
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham ultrasound (US) therapy
Study: 31865815
Drug: Intradermal injection
Normalized name: Dryvax Intradermal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injection of botulinum toxin
Study: 31721257
Drug: PHEN/TPM‐ER (3.75 mg/23 mg-15 mg/92 mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHEN/TPM‐ER (3.75 mg/23 mg-15 mg/92 mg)
Study: 18374841
Drug: Haloperidol (1-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (1-4 mg per day)
Study: 18374841
Drug: Amisulpride (200-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride (200-800 mg per day)
Study: 18374841
Drug: Olanzapine (5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (5-20 mg per day)
Study: 18374841
Drug: Quetiapine (200-750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (200-750 mg per day)
Study: 18374841
Drug: Ziprasidone (40-160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone (40-160 mg per day)
Study: 16326171
Drug: EGG diet
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGG diet (640 mg/d cholesterol)
Study: 16326171
Drug: Placebo diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo diet (0 mg/d cholesterol)
Study: 8237930
Drug: Concurrent illnesses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent illnesses
Study: 30916001
Drug: Intraoperative oliguria
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative oliguria (urinary output <0.5 ml kg‐1 h‐1)
Study: 30916001
Drug: Intraoperative oliguria
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative oliguria (urinary output <0.3 ml kg‐1 h‐1)
Study: 26070528
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with lercanidipine (LER, 10-20mg)
Study: 26070528
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with hydrochlorothiazide (HCT, 12.5-25mg)
Study: 25956055
Drug: Interactive home-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive home-based training delivered through the internet for 30 min daily for 20 weeks